Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
Chronic pain and inflammatory diseases can be regulated by complex mechanisms involving α7 nicotinic acetylcholine receptors (nAChRs), making this subtype a promising drug target for anti-inflammatory therapies. Recent evidence suggests that suchtreatment of inflammatory pain may rely on metabotropic-like rather than ionotropic activation of the α7 receptor subtype in non-neuronal cells. We previously identified para-trifluoromethyl (p-CF3) N,N-diethyl-N'-phenylpiperazinium (diEPP) iodide to be among the compounds classified as silent agonists, which are very weak α7 partial agonists that are able to induce positive allosteric modulator (PAM)-sensitive desensitization. Such drugs have been shown to selectively promote α7 ionotropic-independent functions. Therefore, we here further investigated the electrophysiological profile of p-CF3 diEPP and its in vivo antinociceptive activity using Xenopus oocytes expressing α7, α4β2, or α3β4 nAChRs. The evoked currents confirmed p-CF3 diEPP to be α7-selective with a maximal agonism 5% that of acetylcholine (ACh). Coapplication of p-CF3 diEPP with the type II PAM 4-naphthalene-1-yl-3a,4,5,9b-tetrahydro-3-H-cyclopenta[c]quinoline-8-sulfonic acid amide (TQS) produced desensitization that could be converted to PAM-potentiated currents, which at a negative holding potential were up to 13-fold greater than ACh controls. Voltage-dependence experiments indicated that channel block may limit both control ACh and TQS-potentiated responses. Although no p-CF3 diEPP agonist activity was detected for the heteromeric nAChRs, it was a noncompetitive antagonist of these receptors. The compound displayed remarkable antihyperalgesic and antiedema effects in in vivo assays. The antinociceptive activity was dose and time dependent. The anti-inflammatory components were sensitive to the α7-selective antagonist methyllycaconitine, which supports the idea that these effects are mediated by the α7 nAChR.
Assayag,
Bronchodilatory and anti-inflammatory effects of ASM-024, a nicotinic receptor ligand, developed for the treatment of asthma.
2014, Pubmed
Assayag,
Bronchodilatory and anti-inflammatory effects of ASM-024, a nicotinic receptor ligand, developed for the treatment of asthma.
2014,
Pubmed Bagdas,
New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs.
2018,
Pubmed Bagdas,
The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain.
2016,
Pubmed Bagdas,
The role of alpha5 nicotinic acetylcholine receptors in mouse models of chronic inflammatory and neuropathic pain.
2015,
Pubmed Briggs,
Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.
2009,
Pubmed
,
Xenbase Chaplan,
Quantitative assessment of tactile allodynia in the rat paw.
1994,
Pubmed Chojnacka,
Synthesis and evaluation of a conditionally-silent agonist for the α7 nicotinic acetylcholine receptor.
2013,
Pubmed
,
Xenbase de Jonge,
The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.
2007,
Pubmed de Jonge,
Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway.
2005,
Pubmed Francis,
Muscle-type nicotinic acetylcholine receptor delta subunit determines sensitivity to noncompetitive inhibitors, while gamma subunit regulates divalent permeability.
1996,
Pubmed
,
Xenbase Freitas,
The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models.
2013,
Pubmed Freitas,
Effects of α7 positive allosteric modulators in murine inflammatory and chronic neuropathic pain models.
2013,
Pubmed Fujii,
Expression and Function of the Cholinergic System in Immune Cells.
2017,
Pubmed Gao,
Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain.
2010,
Pubmed Grønlien,
Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes.
2007,
Pubmed
,
Xenbase Guerra-Álvarez,
Positive allosteric modulation of alpha-7 nicotinic receptors promotes cell death by inducing Ca(2+) release from the endoplasmic reticulum.
2015,
Pubmed Halevi,
Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression.
2003,
Pubmed
,
Xenbase Hartung,
Nuclear factor-kappa B regulates pain and COMT expression in a rodent model of inflammation.
2015,
Pubmed Horenstein,
Anti-inflammatory Silent Agonists.
2017,
Pubmed Hurst,
A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.
2005,
Pubmed
,
Xenbase Kabbani,
Are nicotinic acetylcholine receptors coupled to G proteins?
2013,
Pubmed Kabbani,
Beyond the Channel: Metabotropic Signaling by Nicotinic Receptors.
2018,
Pubmed King,
Identification and Characterization of a G Protein-binding Cluster in α7 Nicotinic Acetylcholine Receptors.
2015,
Pubmed Kulkarni,
Microwave-assisted Expeditious and Efficient Synthesis of Cyclopentene Ring-fused Tetrahydroquinoline Derivatives Using Three-component Povarov Reaction.
2013,
Pubmed MCQUEEN,
Use of mecamylamine in the management of hypertension.
1957,
Pubmed Medhurst,
Activation of the alpha7-nicotinic acetylcholine receptor reverses complete freund adjuvant-induced mechanical hyperalgesia in the rat via a central site of action.
2008,
Pubmed MOYER,
Laboratory and clinical observations on mecamylamine as a hypotensive agent.
1955,
Pubmed Munro,
The α7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat.
2012,
Pubmed Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase Papke,
Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states.
2018,
Pubmed
,
Xenbase Papke,
The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor.
2015,
Pubmed
,
Xenbase Papke,
Working with OpusXpress: methods for high volume oocyte experiments.
2010,
Pubmed
,
Xenbase Papke,
The minimal pharmacophore for silent agonism of the α7 nicotinic acetylcholine receptor.
2014,
Pubmed
,
Xenbase Papke,
NS6740, an α7 nicotinic acetylcholine receptor silent agonist, disrupts hippocampal synaptic plasticity.
2018,
Pubmed
,
Xenbase Papke,
Merging old and new perspectives on nicotinic acetylcholine receptors.
2014,
Pubmed Papke,
Inhibition of nicotinic acetylcholine receptors by bis (2,2,6,6-tetramethyl- 4-piperidinyl) sebacate (Tinuvin 770), an additive to medical plastics.
1994,
Pubmed
,
Xenbase Peng,
Multiple modes of α7 nAChR noncompetitive antagonism of control agonist-evoked and allosterically enhanced currents.
2013,
Pubmed
,
Xenbase Pieschl,
Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
2017,
Pubmed Quadri,
Identification of α7 Nicotinic Acetylcholine Receptor Silent Agonists Based on the Spirocyclic Quinuclidine-Δ2 -Isoxazoline Scaffold: Synthesis and Electrophysiological Evaluation.
2017,
Pubmed
,
Xenbase Quadri,
Sulfonium as a Surrogate for Ammonium: A New α7 Nicotinic Acetylcholine Receptor Partial Agonist with Desensitizing Activity.
2017,
Pubmed
,
Xenbase Quadri,
Dissection of N,N-diethyl-N'-phenylpiperazines as α7 nicotinic receptor silent agonists.
2016,
Pubmed
,
Xenbase Thomsen,
The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia.
2012,
Pubmed Tracey,
Physiology and immunology of the cholinergic antiinflammatory pathway.
2007,
Pubmed Williams,
Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.
2011,
Pubmed Williams,
Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.
2011,
Pubmed
,
Xenbase Williams,
Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures.
2012,
Pubmed
,
Xenbase Zdanowski,
Role of α7 nicotinic receptor in the immune system and intracellular signaling pathways.
2015,
Pubmed
